Business Context and Reporting Period
Company: American International Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 31, 2016
Purpose: Regulation FD Disclosure to furnish supplemental slides added to the Company's Investor Presentation previously filed on January 26, 2016, and updated on February 2, 2016, and March 16, 2016.
Key Financial Metrics
This filing serves as a disclosure of updated investor presentation materials and does not contain specific financial statements, revenue figures, profit data, cash flow metrics, margin analysis, debt levels, or liquidity ratios. The filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing reports the addition of supplemental slides to the existing Investor Presentation. No material changes to financial results or operational status are detailed within the text of this specific 8-K report.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to use the Supplemented Investor Presentation in presentations to investors and other stakeholders.
Availability: The presentation is available on the Company's website at www.aig.com.
Legal Status: The information in this report and the attached exhibit is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It shall not be incorporated by reference into any other filings under the Securities Act of 1933 or the Securities Exchange Act of 1934.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Verify the content of the "Supplemented Investor Presentation" (Exhibit 99.1) for specific financial data and strategic updates.
- Confirm the availability of the presentation on the official AIG website (www.aig.com).
- Note that this 8-K filing itself does not constitute a filed financial report under Section 18 of the Exchange Act.
- Review the original Investor Presentation filings from January 26, February 2, and March 16, 2016, to understand the context of the supplements.